MELI, MercadoLibre, Inc.

** On its third quarter fiscal 2011, MELI posted consolidated net revenues of $81.6 million, representing 45.9% year-over-year growth, and gross profit of $61.6 million, a 38.4% increase over the previous year quarter.

MELI is Latin America's leading e-commerce technology company. Through 's primary platforms, MercadoLibre.com and MercadoPago.com, MELI provides solutions to individuals and companies buying, selling, advertising, and paying for goods online.

More about MELI at www.mercadolibre.com

**************

CPE, Callon Petroleum Co.

** CPE reported net income of $8.4 million, or $0.21 per fully diluted share for the third quarter 2011, compared with net income of $1.6 million, or $0.05 per fully diluted share in the same period a year ago.

CPE is engaged in the acquisition, development, exploration and operation of oil and gas properties in Louisiana, Texas, and the offshore waters of the Gulf of Mexico.

More about CPE at www.callon.com

**************

MDVN, Medivation, Inc.

** MDVN and Astellas Pharma Inc. reported that the Independent Data Monitoring Committee (IDMC) has informed the companies of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy.

MDV3100 is an investigational agent that is the first in a new class of medicines called androgen receptor signaling inhibitors.

In October 2009, MDVN and Astellas entered into a global agreement to jointly develop and commercialize MDV3100. The companies are collaborating on a comprehensive development program that includes studies to develop MDV3100 across the full spectrum of advanced prostate cancer. Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the United States and Astellas will have responsibility for commercializing MDV3100 outside the United States.

MDVN is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. MDVN aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

More about MDVN at www.medivation.com.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.